25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
On August 20, 2019, a three-judge panel of the U.S. Court of Appeals for the Ninth Circuit issued an...
Read More >
INTRODUCTION - Part 1 of this distressed M&A series addressed the unique aspects of acquiring distre...
Read More >
As 2019 winds down, employers should keep an eye on the five biggest employment law trends for 2020....
Read More >
The New York City Commission on Human Rights (NYCCHR) has released a factsheet providing guidance on...
Read More >
The Work Injury Compensation Bill 2019 (the Bill) was passed in Parliament on 3 September 2019. Broa...
Read More >
Earlier this month, Governor Pritzker signed into law SB 1557, revising the Recreational Cannabis La...
Read More >